Praxis Precision Medicines (PRAX) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PRAX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Praxis Precision Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$318.22 |
| 52 Week High | US$356.00 |
| 52 Week Low | US$26.70 |
| Beta | 3.01 |
| 1 Month Change | 1.34% |
| 3 Month Change | 70.95% |
| 1 Year Change | 778.82% |
| 3 Year Change | 1,979.87% |
| 5 Year Change | -47.20% |
| Change since IPO | -23.69% |
Recent News & Updates
Recent updates
Praxis: Priced For Perfection Heading Into 2026
Dec 31We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Jul 18
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Apr 04Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Mar 04Praxis Precision Medicines: Multiple Potential Drivers
Dec 26Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Shareholder Returns
| PRAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.1% | 1.2% | -0.6% |
| 1Y | 778.8% | 28.8% | 15.5% |
Return vs Industry: PRAX exceeded the US Biotechs industry which returned 28.8% over the past year.
Return vs Market: PRAX exceeded the US Market which returned 15.5% over the past year.
Price Volatility
| PRAX volatility | |
|---|---|
| PRAX Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRAX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRAX's weekly volatility has decreased from 28% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 168 | Marcio De'Souza | praxismedicines.com |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE.
Praxis Precision Medicines, Inc. Fundamentals Summary
| PRAX fundamental statistics | |
|---|---|
| Market cap | US$9.21b |
| Earnings (TTM) | -US$303.27m |
| Revenue (TTM) | n/a |
Is PRAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRAX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$267.12m |
| Gross Profit | -US$267.11m |
| Other Expenses | US$36.15m |
| Earnings | -US$303.27m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PRAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/03 14:24 |
| End of Day Share Price | 2026/03/03 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Praxis Precision Medicines, Inc. is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |